Can differences in T1 Relaxivity between Gadolinium-based contrast agents be taken advantage of to lower the administered dose of gadolinium?

Jul 13, 2021

Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.21.25924 

Intracranial deposition of gadolinium after contrast-enhanced MRI is an emerging area of concern with much still to be learned. Kalen Riley, MD, MBA discusses a new article that proposes a dose-reduction strategy that takes advantage of relatively higher T1 relaxivity of one macrocyclic agent compared to another while still striving to maintain an adequate imaging examination.